View all hepatitis C drug Patient Group input from HepCBC

We are asking for patients to give us input about a new treatment for genotype 4 patients. Are you curious how we use this data?  Want to see what HepCBC tells BC Pharmacare, or the federal drug review agencies about patients' opinions of new hepatitis C treatments? Exactly what did HepCBC tell them about Daklinza (daclatasvir), Holkira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir), Harvoni (sofosbuvir+ledipasvir), Sovaldi (sofusbovir), Sunpr...

Summer of Interferon-free Hepatitis C Drug Approvals?

2015 is stacking up to have a Summer of Interferon-Free hepatitis C drug approvals! So far we've had the following approvals for provincial Pharmacare coverage (addition to provincial "formulary"):On June 29th, Ontario covered AbbVie's Holkira Pak™ for genotype 1, on July 24th, Quebec covered both Gilead's Harvoni™ and AbbVie's Holkira Pak™ for genotype 1. And on World Hepatitis Day, July 28th British Columbia, Saskatchewan, Manitoba, and Yukon started to ...

Bristol-Myers Squibb’s “Stand-Alone” marketing of daclatasvir worldwide refreshing change

Amadou Diarra, Bristol-Myers Squibb Vice President, Global Policy & Government Affairs, source BMS website We recently praised the Bristol-Myers Squibb (BMS) marketing of daclatasvir as a 'stand-alone' hepatitis C drug which could be easily marketed and combined with other drugs instead of being packaged only with other drugs from the same company in a proprietary "package" (http://hepcbc.ca/2014/10/praise-stand-alone-hcv-drugs/). When our goal is th

Articles on hepatitis C drug SOVALDI international pricing, distribution

Read these articles for the latest news on Gilead's international production, distribution, and pricing of its new hepatitis C drug, SOVALDI:   Article in Bloomberg Mag (Gilead Close to Sending $84,000 Drug to Poor Countries) explaining how/why pricing differs throughout the world: http://www.bloomberg.com/news/2014-09-04/gilead-close-to-sending-84-000-drug-to-poor-countries.html Great quote at the end of this Businessweek article (Britain Has

URGENT REQUEST for patient input into INTERFERON-FREE HCV drug combo: sofosbuvir+ledipasvir

We've been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE drug combo sofosbuvir and ledipasvir (also known as SOVALDI and GS-5885) for Chronic Hepatitis C, developed by Gilead Sciences. We urgently request input from individual HCV+ people (both those who have and have not tried this drug combination, any genotype). For background info see http://hepcbc.ca/contribute-sofosbuvir-ledipasvir-submission-cadth/. For the actual que